<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="101010">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02144259</url>
  </required_header>
  <id_info>
    <org_study_id>813000</org_study_id>
    <nct_id>NCT02144259</nct_id>
  </id_info>
  <brief_title>The Impact of Contraception on Postpartum Weight Loss</brief_title>
  <acronym>PPWL</acronym>
  <official_title>The Impact of Contraception on Postpartum Weight Loss: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective mixed methods study to assess weight changes in women randomized to
      receive Implanon 速 or Depo Provera速 (DMPA) immediately postpartum compared to women who
      choose non-hormonal contraception or no contraception immediately postpartum. After
      enrollment, subjects return for a visit at 3, 6 and 12 months postpartum to be asked a
      series of questions, take a pregnancy test, and be weighed. Total length of participation
      for each subject is 1 year or until pregnancy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Weight change</measure>
    <time_frame>6 months postpartum</time_frame>
    <safety_issue>No</safety_issue>
    <description>Weight will be measured at 3, 6 and 12 months postpartum. Percent weight change will be compared amongst the groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary outcome variables is pregnancy rate. Pregnancy testing will occur at 3, 6 and 12 months postpartum.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Contraceptive satisfaction</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Satisfaction will be measured by the occurrence of unscheduled clinical visits to other facilities and responses to a series of questions to assess contraceptive continuation rates, contraceptive satisfaction, and bleeding patterns.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Weight</condition>
  <arm_group>
    <arm_group_label>DMPA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to receive DepoProvera(DMPA) immediately post-partum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Implanon group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to receive Implanon immediately post-partum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects selecting their own method of contraception or no contraception.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMPA immediately postpartum</intervention_name>
    <description>DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.</description>
    <arm_group_label>DMPA group</arm_group_label>
    <other_name>DepoProvera, depot medroxyprogesterone acetate (DMPA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Implanon immediately postpartum</intervention_name>
    <description>Implanon 速 is a subdermal implant that contains 68mg of etonogesterel.</description>
    <arm_group_label>Implanon group</arm_group_label>
    <other_name>etonogestrel implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English speaking

          -  Aged 18-45 at enrollment (inclusive)

          -  Immediately postpartum of a live singleton infant, 37 weeks gestation, at HUP

          -  Desiring to delay another pregnancy for 6 months

          -  Willing and able to follow the study protocol

        Exclusion Criteria:

          -  Breastfeeding during study participation

          -  Plans for relocation outside of Philadelphia in the next six months

          -  Plans for use of weight loss medication or diet pills in the next six months

          -  Women who wish to start Implanon 速 or DMPA prior to discharge but who do not want to
             be randomized. 5. Issues or concerns in the judgment of the investigator that may
             compromise the safety of the subject or confound the reliability of compliance and
             information acquired in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Courtney A Schreiber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>May 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Courtney Schreiber</investigator_full_name>
    <investigator_title>Director, Fellowship in Family Planning</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>3-keto-desogestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
